64
Participants
Start Date
September 4, 2020
Primary Completion Date
December 1, 2022
Study Completion Date
February 18, 2024
Lenvatinib
Capsules administered orally once daily
Tislelizumab
200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Peking Union Medical College Hospital, Beijing
Harbin Medical University Cancer Hospital, Harbin
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Anhui Provincial Hospital, Hefei
Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou
Sun Yat Sen University Cancer Center, Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
West China Hospital, Sichuan University, Chengdu
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
Lead Sponsor
BeiGene
INDUSTRY